Health Care Resource Utilization of Late Premature Versus Term Infants With Bronchiolitis.
Antiviral Agents
/ therapeutic use
Bronchiolitis
/ prevention & control
Cost-Benefit Analysis
Female
Gestational Age
Hospitalization
Humans
Infant
Infant, Newborn
Infant, Premature
Infant, Premature, Diseases
Israel
Male
Palivizumab
/ therapeutic use
Respiratory Syncytial Virus Infections
/ prevention & control
Retrospective Studies
Utilization Review
RSV prophylaxis
bronchiolitis
health care resource utilization
late premature infants
palivizumab
Journal
Clinical pediatrics
ISSN: 1938-2707
Titre abrégé: Clin Pediatr (Phila)
Pays: United States
ID NLM: 0372606
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
pubmed:
14
5
2020
medline:
29
12
2020
entrez:
14
5
2020
Statut:
ppublish
Résumé
It is controversial whether it is cost-beneficial for late preterm infants to receive respiratory syncytial virus prophylaxis. This study compares community and hospital health care resource utilization (HCRU) of late premature infants (33-36 weeks gestational age) with term infants (>36 weeks gestational age) hospitalized with bronchiolitis. This was a retrospective, population-based, observational study spanning a 9-year period (2004-2012). HCRU data were obtained from the Health Maintenance Organization "Clalit" and included duration of hospitalization, physician visits, laboratory tests, and treatments. Compared with term infants, late preterm infants had significantly longer duration of hospitalization and higher admission rates to pediatric intensive care unit. They also had higher rates of mean outpatients clinic visits, total outpatient clinic and specialist visits, blood chemistry, and virology testing. HCRU of term infants with bronchiolitis was also substantial, indicating that they also can greatly benefit from respiratory syncytial virus prophylaxis. These findings can guide stakeholders in decisions concerning the prevention of bronchiolitis and will be useful in performing further cost-benefit analysis.
Identifiants
pubmed: 32400172
doi: 10.1177/0009922820920012
doi:
Substances chimiques
Antiviral Agents
0
Palivizumab
DQ448MW7KS
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM